InsiderSignal.AI

InsiderSignal.ai

CABA - Cabaletta Bio, Inc.

Insider Purchase by Nichtberger Steven (Pres, CEO)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

1 month ago, Nichtberger Steven, serving as Pres, CEO at Cabaletta Bio, Inc. (CABA), purchased 45,000 shares at $2.24 per share, for a total transaction value of $100,778.00. Following this transaction, Nichtberger Steven now holds 1,394,483 shares of CABA.

This purchase represents a 3.00% increase in Nichtberger Steven's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, January 21, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, January 21, 2026, meaning the disclosure happened on the same day as the trade.

Cabaletta Bio, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Nichtberger Steven

Nichtberger Steven

Pres, CEO

Steven Nichtberger, M.D. is the President, Chief Executive Officer, Chairman, and Co-Founder of Cabaletta Bio, Inc. (NASDAQ: CABA), a clinical-stage biotechnology company developing targeted cellular therapies, particularly CAR T therapies, for B cell-mediated autoimmune diseases.[[1]](https://www.cabalettabio.com/investors/company-information/management-team)[[2]](https://www.cabalettabio.com/investors/corporate-governance/board-of-directors)[[3]](https://www.youtube.com/watch?v=N_0xngBju1k)[[5]](https://www.whcbc.org/pulse/targeted-cell-therapy-for-autoimmune-diseases-a-conversation-with-steven-nichtberger-ceo-of-cabaletta-bio/) He has led the company since its founding in 2017, spun out from the University of Pennsylvania, and recently purchased 45,000 shares on January 21, 2026, at an average price of $2.2395, bringing his direct ownership to over 1 million shares.[[1]](https://www.cabalettabio.com/investors/company-information/management-team)[[4]](https://www.investing.com/news/insider-trading-news/cabaletta-bio-caba-ceo-nichtberger-buys-100777-in-shares-93CH-4459142)[[6]](https://www.marketbeat.com/instant-alerts/steven-nichtberger-acquires-45000-shares-of-cabaletta-bio-nasdaqcaba-stock-2026-01-21/) Dr. Nichtberger's career highlights include serving as founding CEO of Tengion from 2004 to 2011, where he earned the Ernst & Young Entrepreneur of the Year award in 2008, and earlier roles at Merck from 1995 to 2003 as head of global marketing and in commercial operations.[[1]](https://www.cabalettabio.com/investors/company-information/management-team)[[2]](https://www.cabalettabio.com/investors/corporate-governance/board-of-directors) He is a senior fellow and adjunct professor at the Wharton School of the University of Pennsylvania, serves on the executive committee of Main Line Health's board of governors, and has held board positions with the Alliance for Regenerative Medicine, Pennsylvania Bio, and Biotechnology Industry Organization.[[1]](https://www.cabalettabio.com/investors/company-information/management-team) Dr. Nichtberger holds an M.D. from the State University of New York at Buffalo, a B.S. from the Wharton School, and a B.A. from the College of Arts & Sciences at the University of Pennsylvania, with medical training completed at Mount Sinai Medical Center.[[1]](https://www.cabalettabio.com/investors/company-information/management-team)

View full insider profile →

Trade Price

$2.24

Quantity

45,000

Total Value

$100,778.00

Shares Owned

1,394,483

Trade Date

Wednesday, January 21, 2026

32 days ago

SEC Filing Date

Wednesday, January 21, 2026

HEALTHCAREBIOTECHNOLOGY

About Cabaletta Bio, Inc.

Company Overview

No company information available
View news mentioning CABA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3307001

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime